The SCID-hu xenogeneic transplantation model allows screening of anti-psoriatic drugs

Archives of Dermatological Research

Volumn 291, Issue 2-3, 1999, Pages 104-106

  Boehncke, Wolf Henning ^a   Kock, Martin ^a   Hardt Weinelt, Katja ^a   Wolter, Manfred ^a  

^a GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

Author keywords

Animal model; Drug; Psoriasis; SCID mouse; Therapy

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; DEXAMETHASONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; STEROID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASE REPORT; DERMIS; DRUG SCREENING; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSORIASIS; SCID MOUSE; SKIN GRAFT; T LYMPHOCYTE ACTIVATION; XENOGRAFT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; MICE, SCID; PSORIASIS; QUINOLINES; SKIN TRANSPLANTATION;

EID: 0032972579     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004030050391     Document Type: Article

References (13)

1. Beamer WG, Pelsue SC, Shultz LD, Sundberg JP, Barker JE (1995) The flaky skin (fsn) mutation in mice: map location and description of the anemia. Blood 86:3220-3226
2. Boehncke W-H (1997) Animal models for psoriasis. Hautarzt 48: 707-713
3. Boehncke W-H, Dressel D, Zollner TM, Kaufmann R (1996) Pulling the trigger on psoriasis. Nature 379:777
4. Boehncke W-H, Sterry W, Hainzl A, Scheffold W, Kaufmann R (1994) Psoriasiform architecture of murine epidermis overlying human psoriatic dermis transplanted onto SCID mice. Arch Dermatol Res 286:325-330
5. Bosma GC, Custer RP, Bosnia MJ (1983) A severe combined immunodeficiency mutation in the mouse. Nature 301:527-530
6. Camp RDR, Mallet AI, Woollard PM, Brain SD, Kobza Black A, Greaves MW (1983) The identification of hydroxy fatty acids in psoriatic skin. Prostaglandins 26:431-447
7. Christophers E (1996) The immunopathology of psoriasis. Int Arch Allergy Immunol 110:199-206
8. 2α in epidermis of psoriasis. Proc Natl Acad Sci (USA) 72:5130-5134
9. Henseler T (1998) The genetics of psoriasis. Arch Dermatol Res 290:463-476
10. De Jong EMGJ, van Vlijmen IMMJ, Scholte JCM et al. (1991) Clinical and biochemical effects of an oral leukotriene biosynthesis inhibitor (MK-886) in psoriasis. Skin Pharmacol 4: 278-285
11. Müller-Peddinghaus R, Kast R (1996) Leukotriene synthesis (FLAP) inhibition: biochemistry and pharmacology of BAY X 1005. In: Folco, Samuelsson, Maclouf, Velo (eds) Eicosanoids: from biotechnology to therapeutic applications. Plenum Press, New York, pp 195-204
12. Sundberg JP, Boggess D, Shultz LD, Beamer WG (1994) The flaky skin mutation, chromosome? In: Sundberg JP (ed) Handbook of mouse mutations with skin and hair abnormalities: animal models and biochemedical tools. CRC Press, Boca Raton, pp 253-268
13. Wrone-Smith T, Nickoloff BJ (1996) Dermal injection of immunocytes induces psoriasis. J Clin Invest 98:1878-1887